Cerebral, a mental health management platform provider, has acquired attention-deficit/hyperactivity disorder (ADHD) app developer Inflow, advancing the former’s mental health services.
Grounded in cognitive behavioural therapy (CBT) principles, Inflow’s ADHD app helps subscribers with daily skills-based modules to help them build awareness, change habits, and manage their ADHD day-to-day. Past research into the app has demonstrated its efficacy in decreasing users’ symptoms and impairment on a self-reported basis.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Cerebral claims that by acquiring Inflow, for which financial terms have not been publicly disclosed, the California-based company will be able to offer “continuous support options” to ADHD patients beyond appointment management.
Cerebral’s chief medical officer, Dr Carl Marci, commented: “High-quality ADHD treatments are a significant and growing area of need, underscoring the importance of scalable, validated tools that offer support both during and in between sessions.”
Other companies involved in the digital ADHD treatment space include Lumos Labs, which gained US Food and Drug Administration (FDA) clearance in December 2025 for LumosityRx, a prescription digital therapeutic (PDT) that aims to improve attention span in adult patients with ADHD through cognitive training games that are intended for use alongside other ADHD treatment modalities such as medication and therapy.
Meanwhile, in June 2024, Akili gained FDA clearance for EndeavorOTC, the first over-the-counter (OTC) video game-based ADHD treatment to be cleared by the agency. EndeavorOTC is a phone-based ‘infinite runner’ game. In Akili’s STARS-ADHD-Adult trial (NCT05183919), 72.5% of patients reported at least some improvement to their quality of life (QoL) after engaging with the game, as measured on the Adult ADHD Quality of Life Scale.
A report by GlobalData forecasts that there will be a minor rise in ADHD cases across the seven major markets (7MM; the US, Japan, Germany, France, the UK, Italy, and Spain) due to standardised screening tools and guidelines. The number of diagnosed prevalent cases of the disorder is expected to grow from 21.1 million in 2022 to 22 million by 2032.
